Oramed Pharmaceuticals
ORMP on XNAS, Oramed Pharmaceuticals Inc.
Measures activity, not value. Not investment advice.
Bought, last 12 months
$0
vs the 12 months before
Sold, last 12 months
$1.2M
vs the 12 months before
Net, last 12 months
-$1.2M
bought minus sold
Sharp changes
1
clustered insider buying
What usually follows Companies in the top fifth of insider net purchases (90 days, per $1M of company value, in $100s) beat their sector by a median 0.3 points over the next 6 months, against +2.6 points for the bottom fifth. Clear How we measured it
Who traded
Insiders with counted open-market trades, largest total first. Each name opens every trade of that person, at every company| Insider | Role | Purchases | Sales | Latest trade |
|---|---|---|---|---|
| Nadav Kidron | President and CEO | 4$262K | 2$4.4M | 16 Mar 2023 |
| Miriam Kidron | Chief Scientific Officer | – | 3$1.3M | 14 Mar 2023 |
| Xiaopeng Li | Director | 2$1.1M | – | 2 Aug 2017 |
| Joshua Hexter | COO & CBO | – | 2$746K | 1 Oct 2026 |
| Kevin Rakin | Director | – | 2$537K | 21 Mar 2022 |
| Avraham Gabay | Chief Financial Officer | – | 2$421K | 1 Oct 2026 |
| Leonard Sank | Director | 3$273K | – | 9 Sep 2019 |
| Michael Rabinowitz | Chief Commercial Officer | – | 1$167K | 3 Jan 2023 |
| Yadin Rozov | Director | 1$142K | – | 13 Mar 2023 |
| Arie Mayer | Director | 1$20K | 1$77K | 3 Apr 2023 |
| Harold Jacob | Director | – | 1$55K | 10 Mar 2016 |
| Aviad Friedman | Director | 1$12K | – | 9 Aug 2018 |
Form 4 open-market trades, by trade date.
See the numbers
| Month of Oct 2026: bought $0, sold $226K |
| Month of Jul 2026: bought $0, sold $942K |
| Month of Apr 2023: bought $20K, sold $0 |
| Month of Mar 2023: bought $396K, sold $201K |
| Month of Jan 2023: bought $0, sold $167K |
| Month of May 2022: bought $0, sold $77K |
| Month of Mar 2022: bought $0, sold $94K |
| Month of Sep 2021: bought $0, sold $443K |
| Month of Aug 2021: bought $0, sold $4.4M |
| Month of Sep 2019: bought $73K, sold $0 |
| Month of Jul 2019: bought $200K, sold $0 |
| Month of Aug 2018: bought $12K, sold $0 |
| Month of Jul 2018: bought $722, sold $365 |
| Month of Aug 2017: bought $762K, sold $762K |
| Month of Apr 2017: bought $334K, sold $334K |
What the numbers say
- Bought $0 vs sold $1.2M in the 12 months to Oct 2026.
- Insider net buying over 12 months: -$1.2M, number 384 of 658 Health Care companies with data (median -$372K).
- 1 sharp change in all loaded history (clustered insider buying).
- Open-market trades in the last 12 months by who traded: the largest is officers sold, $1.2M (100%).
- Latest record: Gabay Avraham (Chief Financial Officer) sold 20,000 shares of ORMP ($90,200), public on 2 Oct 2026.
See the numbers
| Officers sold | $1.2M (100%) |
Every measure from this source
5 years, by the period each figure describes
Sharp changes
1 in all loaded history, strongest first
Oramed Pharmaceuticals had 3 insiders buy $415K of its shares on the open market within 30 days (4 filings).
Who bought: Rozov Yadin, Kidron Nadav, Mayer Arie.
See the evidence (4 source records)
- Independent buyers
- 3
- Purchase filings (Form 4, code P)
- 4
- Total bought
- $415K
- Window
- 6 Mar 2023 to 5 Apr 2023
- Rozov Yadin (director) bought 70,000 shares of ORMP ($141,700)dated 15 Mar 2023, public 16 Mar 2023
- KIDRON NADAV (President and CEO) bought 100,000 shares of ORMP ($201,000)dated 15 Mar 2023, public 16 Mar 2023
- KIDRON NADAV (President and CEO) bought 26,000 shares of ORMP ($53,040)dated 16 Mar 2023, public 17 Mar 2023
- Mayer Arie (director) bought 8,809 shares of ORMP ($19,518)dated 4 Apr 2023, public 5 Apr 2023
Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.
The records
Newest first, by the day each became public